CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.
CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.
Experts say this means drugmakers need to find new ways to communicate the value of their products.
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.
States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The drugmaker instead suggested using an economic model it developed.
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad
The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.